Drugs / ABT-072
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT00982826 | Sep → Dec 2009 | hepatitis C virus infection | Abbott | Completed | No outcome recorded |
| Phase 1 | NCT00890318 | Apr → Jul 2009 | hepatitis C virus infection | Abbott | Completed | No outcome recorded |
| Phase 1 | NCT00752687 | Sep 2008 → May 2009 | hepatitis C virus infection | Abbott | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01221298 | Oct 2010 → May 2011 | chronic hepatitis C virus infection | AbbVie | Completed | No outcome recorded |
| Phase 2 | NCT01074008 | Mar 2010 → Jun 2011 | chronic hepatitis C virus infection | AbbVie | Completed | No outcome recorded |
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01081483 Comparator | Mar → Jun 2010 | hepatitis C virus infection | Abbott | Completed | No outcome recorded |
| Phase 1 | NCT00947440 Comparator | Jul → Aug 2009 | hepatitis C virus infection | Abbott | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00872196 Background | Apr 2009 → Apr 2010 | hepatitis C virus infection | AbbVie | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABT-072 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00947440 ↗ |
| Action | Inhibit | “ABT-072 is a non-nucleoside NS5B polymerase inhibitor” PMID 23439262 ↗ Feb 2013 |
| Modality | Small molecule | — CHEMBL4076467 ↗ |
| Route | Oral | “blinded, single ascending oral doses of ABT 072” NCT01081483 ↗ |